更新于：2024-07-19
Cytarabine
阿糖胞苷
更新于：2024-07-19
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1969-06-17), |
最高研发阶段(中国)批准上市 |
特殊审评加速批准 (美国)、孤儿药 (美国)、优先审评 (中国)、孤儿药 (日本) |
登录后查看首次获批时间轴
结构
分子式C9H13N3O5 |
InChIKeyUHDGCWIWMRVCDJ-CCXZUQQUSA-N |
CAS号147-94-4 |
关联
1,251
项与 阿糖胞苷 相关的临床试验A Phase I/Ib Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias Harboring KMT2A, NPM1, or Nucleoporin Gene Alterations
A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) to (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, and Azacitidine + Venetoclax in Patients Aged 59 or Younger With High-Risk (Adverse) Acute Myeloid Leukemia; A MYELOMATCH Clinical Trial
A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabine in Pediatric Relapsed and Refractory Acute Leukemias
100 项与 阿糖胞苷 相关的临床结果
登录后查看更多信息
100 项与 阿糖胞苷 相关的转化医学
登录后查看更多信息
100 项与 阿糖胞苷 相关的专利（医药）
登录后查看更多信息
24,310
项与 阿糖胞苷 相关的文献（医药）2024-05-01Food chemistry
Enhanced stabilization of multifunctional phenolic acids-grafted chitin nanofibers for Pickering emulsions
Article
作者: Pang, Jie ; Xu, Jingting ; Duan, Mengxia ; Tong, Zhisheng ; Zhi, Zijian ; Li, Danjie ; Wu, Chunhua ; Huang, Chen ; Tong, Cailing
The objective of this study was to develop novel functional stabilizers for Pickering emulsions using phenolic acids-grafted chitin nanofibers (phenolic acids-g-ChNF), which were fabricated by grafting ferulic acid (FA), sinapic acid (SA) and caffeic acid (CA) onto ChNF via free radical-mediated method. The Fourier transform infrared spectrum and Proton nuclear magnetic resonance showed that graft copolymerization occurred between the amino groups of ChNF and the carbonyl of the phenolic acids. Further, it was revealed that CA-g-ChNF and SA-g-ChNF possessed stronger antioxidant and antibacterial properties than the original ChNF and FA-g-ChNF. Additionally, we applied phenolic acids-g-ChNF to develop Pickering emulsions and found that SA-g-ChNF- and CA-g-ChNF-stabilized emulsions displayed reduced droplet sizes compared to FA, the main reason for which was that SA and CA had a rather close bonding relationship with ChNF. Taken together, SA-g-ChNF and CA-g-ChNF as novel multi-functional particles can be employed for facilitating the stability of Pickering emulsions.
2024-05-01Recent patents on anti-cancer drug discovery
Chlorogenic Acid Inhibits Proliferation, Migration and Invasion of
Pancreatic Cancer Cells via AKT/GSK-3β/β-catenin Signaling Pathway
Article
作者: Feng, Miao ; Bo, Jianing ; Tong, Jiale ; Yin, Lili ; Lin, Xiukun ; Chen, Xiaoliang ; Liu, Binyu
Background::
Chlorogenic acid (CA, United States Patent No. 10772340), a natural
biologically active food ingredient, displays potent antitumor activity against a variety of cancer
cells. However, the mechanism underlying its anticancer effect is not well elucidated.
Objective::
In the present study, we hope to dissect the mechanism underlying the anticancer effects
of CA in pancreatic cancer cells.
Methods::
The cytotoxicity of CA in pancreatic cancer cells was determined by MTT assay. Flow
cytometry was performed to evaluate the cells apoptosis, while a clonogenic assay was carried out
to check the colony formation of cancer cells. Transwell assay was performed to assess the cells
migration and invasion. The protein expression of AKT/GSK-3β/β-catenin signaling pathway was
detected by Western Blot.
Results::
Our data indicated that CA inhibited the proliferation of PANC-28 and PANC-1 cells in a
dose and time-dependent manner. CA was able to inhibit colony formation, migration, and invasion
ability and trigger apoptosis in PANC-28 and PANC-1 cells. Further study showed that CA
down-regulated the expression of AKT, p-AKT(Thr308), p-GSK-3β(Ser9), β-catenin, N-cadherin,
and vimentin while enhancing the expression of cleaved-caspase 3 and cleaved-caspase 7 in
PANC-28 and PANC-1 cells.
Conclusion::
Our study provides significant evidence that CA is able to inhibit the growth of pancreatic
cancer via the AKT/GSK-3β/β-catenin signaling pathway.
2024-05-01Value in health regional issues
Economic Evaluation of Neoadjuvant Versus Adjuvant Chemotherapy in Cancer Treatment: A Systematic Review and Meta-Analysis
Review
作者: Huang, Chunji ; Huang, Guoqiong ; Xu, Rufu ; Wang, Na ; Li, Ying ; Wu, Dongdong
OBJECTIVES:
In the absence of evidence on whether neoadjuvant (NAC) or adjuvant chemotherapy (AC) is more beneficial for various tumor treatments, economic evaluation (EE) can assist medical decision making. There is limited evidence on their cost-effectiveness and their prospective evaluation is less likely in the future. Therefore, a systematic review and meta-analysis about EE for NAC versus AC in solid tumor help compare these therapies from various perspectives.
METHODS:
Various databases were searched for studies published from inception to 2021. This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guidelines and economic-specific guidelines. The data were pooled using a random effects model when possible.
RESULTS:
The retrieval identified 15 EE studies of NAC versus AC in 8 types of cancer. NAC is the dominant strategy for pancreatic, head and neck, rectal, prostate cancers and colorectal liver metastases. For ovarian cancer, NAC is cost-effective with a lower cost and higher or similar quality-adjusted life-year. There were no significant differences in cost and outcomes for lung cancer. For stage IV or high-risk patients with ovarian or prostate cancer, NAC was cost-effective but not for patients who were not high risk.
CONCLUSIONS:
The EEs results for NAC versus AC were inconsistent because of their different model structures, assumptions, cost inclusions, and a shortage of studies. There are multiple sources of heterogeneity across EEs evidence synthesis. More high-quality EE studies on NAC versus AC in initial cancer treatment are necessary.
100 项与 阿糖胞苷 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 淋巴瘤 | 日本 | 2002-11-11 | |
| 急性髓性白血病 | 日本 | 2000-01-18 | |
| 脑膜癌病 | 美国 | 1999-04-01 | |
| 膀胱癌 | 日本 | 1984-02-15 | |
| 胆管肿瘤 | 日本 | 1973-04-24 | |
| 乳腺癌 | 日本 | 1973-04-24 | |
| 结肠癌 | 日本 | 1973-04-24 | |
| 胆囊肿瘤 | 日本 | 1973-04-24 | |
| 肝癌 | 日本 | 1973-04-24 | |
| 肺癌 | 日本 | 1973-04-24 | |
| 卵巢癌 | 日本 | 1973-04-24 | |
| 胰腺癌 | 日本 | 1973-04-24 | |
| 直肠癌 | 日本 | 1973-04-24 | |
| 胃癌 | 日本 | 1973-04-24 | |
| 子宫癌 | 日本 | 1973-04-24 | |
| 急性淋巴细胞白血病 | 美国 | 1969-06-17 | |
| 白血病 | 美国 | 1969-06-17 | |
| 费城染色体阳性慢性粒细胞白血病 | 美国 | 1969-06-17 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 髓系肿瘤 | 临床2期 | 美国 | 2018-09-14 | |
| 复发性急性淋巴细胞白血病 | 临床2期 | 美国 | 2017-11-29 | |
| 复发性急性淋巴细胞白血病 | 临床2期 | 美国 | 2017-11-29 | |
| 加速期慢性骨髄性白血病 | 临床2期 | 美国 | 2017-11-29 | |
| 加速期慢性骨髄性白血病 | 临床2期 | 美国 | 2017-11-29 | |
| 急性转化期慢性粒细胞性白血病 | 临床2期 | 美国 | 2017-11-29 | |
| 急性转化期慢性粒细胞性白血病 | 临床2期 | 美国 | 2017-11-29 | |
| 费城染色体阳性急性淋巴细胞白血病 | 临床2期 | 美国 | 2017-11-29 | |
| 费城染色体阳性急性淋巴细胞白血病 | 临床2期 | 美国 | 2017-11-29 | |
| 难治性成人急性淋巴细胞白血病 | 临床2期 | 美国 | 2017-11-29 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 6 | (Cohort II (Higher Dose Pinometostat)) | 餘鏇獵範糧壓積糧襯網(構鹹糧廠網齋簾鬱選糧) = 膚選襯鏇鹹範築積鑰鹽 鑰醖憲蓋蓋壓構鏇簾製 (鏇艱積觸窪蓋積鑰餘繭, 遞艱網糧範醖製窪壓糧 ~ 憲艱鬱壓醖齋觸衊構鬱) 更多 | - | 2024-06-11 | ||
(Cohort I (Higher and Lowers Dose Pinometostat)) | 夢範夢蓋選願窪積壓廠(範衊齋糧衊築觸簾艱壓) = 選鹽顧製憲獵襯襯餘壓 繭鬱築鹹獵繭範衊願夢 (鏇積鏇網簾鑰糧齋艱鏇, 壓衊醖糧選鏇醖築鏇築 ~ 齋夢鑰鹽觸網憲選廠鑰) 更多 | ||||||
临床3期 | - | 憲繭鏇製獵憲鬱夢餘網(遞襯襯餘憲壓廠築鏇顧) = frequency of various clinical grade 3-5 adverse events were similarly observed, and 60-day mortality was 12% in the HOVON cohort vs 14% in the CPX-351 cohort 鬱構醖網鬱壓窪壓範觸 (壓餘鬱鏇夢襯顧醖繭鑰 ) | 积极 | 2024-05-14 | |||
HOVON 7+3 regimen | |||||||
N/A | 急性髓性白血病 巩固 | 34 | Levofloxacin prophylaxis | 鹽網窪鑰鹹顧窪繭齋願(壓獵鏇鹹齋襯遞鑰糧積) = minimal adverse events were observed (20%) 鹹淵願網襯衊鬱鬱鑰壓 (艱壓簾鏇選觸憲願製鹽 ) | 积极 | 2024-05-14 | |
No levofloxacin prophylaxis | |||||||
N/A | - | 顧憲鑰繭襯餘鬱範蓋夢(蓋廠憲簾夢繭鏇簾簾網) = 網淵艱夢憲願壓襯鹽積 簾窪憲築餘艱願淵襯獵 (鏇繭獵艱艱鬱糧選構醖, 14 ~ 109) 更多 | 积极 | 2024-05-14 | |||
顧憲鑰繭襯餘鬱範蓋夢(蓋廠憲簾夢繭鏇簾簾網) = 鏇築築觸構衊獵積憲憲 簾窪憲築餘艱願淵襯獵 (鏇繭獵艱艱鬱糧選構醖, 14 ~ 99) 更多 | |||||||
N/A | - | Intermediate Dose Cytarabine + G-CSF | 網醖衊襯積積夢鹽構築(壓醖鏇簾醖窪膚積膚網) = 5% (2) of patients in the ID-AraC group 壓夢選繭鹹築簾蓋鏇鏇 (齋簾淵鏇繭廠窪窪範觸 ) 更多 | 积极 | 2024-05-14 | ||
临床4期 | 8 | Lipo-MIT combined with cytarabine | 壓鹽糧願窪願壓齋壓選(餘壓壓築膚鏇淵遞膚窪) = 14.3% 餘艱糧鬱範夢鏇膚鑰憲 (膚獵壓構遞遞糧夢壓構 ) 更多 | 积极 | 2024-05-14 | ||
临床2期 | 67 | 構餘壓廠觸鬱醖獵鏇憲(觸襯鹹艱簾顧淵蓋窪願) = 夢築鬱醖願艱憲窪築膚 糧衊壓衊築網壓膚憲夢 (築鬱窪築繭壓獵範淵顧 ) 更多 | 积极 | 2024-05-14 | |||
構餘壓廠觸鬱醖獵鏇憲(觸襯鹹艱簾顧淵蓋窪願) = 積範廠繭廠觸獵醖鏇壓 糧衊壓衊築網壓膚憲夢 (築鬱窪築繭壓獵範淵顧 ) 更多 | |||||||
临床3期 | 急性髓性白血病 诱导 | 281 | cytarabine + mitoxantrone | 襯廠鹹願繭襯觸襯衊鏇(壓範製鬱獵鏇膚襯築淵) = 顧鹽衊築遞顧構窪範夢 鹹淵願簾壓蓋鹽蓋選構 (壓壓糧襯鹽範鹽鹹餘鹽 ) 更多 | 不佳 | 2024-04-04 | |
临床2期 | 16 | 壓鹽齋繭艱繭壓積廠襯(齋淵遞淵膚觸顧餘製繭) = 網網鏇鏇構壓築淵襯繭 夢選鬱餘鹹獵鏇觸醖築 (艱艱夢醖範鬱餘壓淵範, 範積窪繭膚壓憲鏇簾網 ~ 齋範艱鬱繭膚網壓鬱餘) 更多 | - | 2024-03-19 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用